ThesisThe recent contract win and expansion into herbal medicines are expected to drive revenue growth, offsetting margin pressures from rising raw material costs.
01Sandu Pharmaceuticals is in the process of launching a new line of herbal medicines, projected to capture a 5% market share in the herbal segment within two years.
02The company has secured a new contract for manufacturing generic drugs for a major international client, expected to increase revenue by 15% over the next fiscal year.
03The company is exploring partnerships with local healthcare providers to enhance distribution channels, which could improve market penetration by 10%.
04Growth in the herbal medicine market
05Expansion of telemedicine and digital health solutions
06Changes in regulatory policies affecting drug approvals in India
07Market share gains in the generic pharmaceuticals sector
08Fluctuations in raw material costs impacting gross margins
